<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00881439</url>
  </required_header>
  <id_info>
    <org_study_id>ARIANA</org_study_id>
    <nct_id>NCT00881439</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Add On Aliskiren in Patients With Heart Failure and Renal Impairment</brief_title>
  <acronym>ARIANA-CHF-RD</acronym>
  <official_title>A Double-blind, Placebo-controlled, Randomized Trial Investigating the Safety and Efficacy of Additive Renin Inhibition With Aliskiren on Renal Blood Flow and Neurohormonal Activation in Patients With Chronic Heart Failure and Renal Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to examine the effect of add-on therapy with the direct
      renin inhibitor Aliskiren in comparison to placebo on renal blood flow in patients with heart
      failure and reduced renal function.

        -  Primary outcome measure: change in renal blood flow at 6 months

        -  Secondary outcome measures: changes in renal function, N-terminal pro Brain natriuretic
           peptide, left ventricular function, blood pressure and neurohormones
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blind, placebo controlled, parallel group comparison
      trial, enrolling 100 patients (67 vs. 33) with stable CHF. Patients will be randomized to
      Aliskiren 300 mg once daily or corresponding Placebo for a period of 6 months. Efficacy
      measures will be performed at baseline and at the end of the study. Primary efficacy outcome
      is change in renal blood flow as measured by 131I-Hippuran clearance. Secondary outcome
      include change in renal function, neurohormones, left ventricular function and blood
      pressure. Safety assessments include renal function, changes in electrolytes, and blood
      pressure. Patients will be uptitrated to maximum tolerated doses of Aliskiren, and safety
      visits are planned 1 week after initiation and on a 2 month interval afterwards. A total of 8
      visits are planned during the entire study period.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Futility
  </why_stopped>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in renal blood flow as assessed by 131I-Hippuran clearance</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in glomerular filtration rate (GFR) as assessed by 125I-Iothalamate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic and diastolic blood pressure</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in N-terminal pro brain natriuretic peptide levels (NT-proBNP)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular ejection fraction</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in NYHA class, change in filtration fraction, change in albumin excretion, change in tubular function parameters, change in neurohormonal activation</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Heart Failure</condition>
  <condition>Kidney Failure</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>Oral, 300 mg, once daily, 6 months</description>
    <arm_group_label>Aliskiren</arm_group_label>
    <other_name>Rasilez</other_name>
    <other_name>SPP100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo once daily, 6 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NYHA II-IV Heart Failure

          -  Left ventricular ejection fraction &lt; 45%

          -  Stable heart failure medication

          -  eGFR by sMDRD formula between 30 and 60 mL/min/1.73m2

        Exclusion Criteria:

          -  Known hypersensitivity to study drug or ACEi

          -  Concomitant treatment with both ARB and Aldosterone Receptor Antagonist

          -  Symptomatic Hypotension

          -  Acute Heart Failure

          -  History of stroke, acute coronary syndrome, PCI or angioplasty within past 3 months

          -  Serum potassium &gt; 5.2 mmol/L

          -  Right heart failure due to severe pulmonary disease

          -  Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A, Lewsey J; Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008 May;1(1):17-24. doi: 10.1161/CIRCHEARTFAILURE.107.740704.</citation>
    <PMID>19808266</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2009</study_first_submitted>
  <study_first_submitted_qc>April 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2009</study_first_posted>
  <last_update_submitted>May 16, 2013</last_update_submitted>
  <last_update_submitted_qc>May 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>H.L. Hillege</investigator_full_name>
    <investigator_title>Prof.dr.</investigator_title>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Renal Failure</keyword>
  <keyword>Cardiorenal Syndrome</keyword>
  <keyword>Renin inhibition</keyword>
  <keyword>Aliskiren</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

